Highlights

  • Argent BioPharma expanded its CannEpil licensing agreement to include veterinary applications.
  • The addendum introduces a separate 10% perpetual Royalty stream on veterinary net sales alongside the existing 15% human-use royalty.
  • Argent retains CannEpil intellectual property, Manufacturing know-how and development rights across human and animal applications.
  • The company previously used its CannEpil licensing arrangement to eliminate existing Debt obligations.

Argent BioPharma (ASX:RGT) has expanded its exclusive global licensing agreement for CannEpil® to include veterinary applications, creating an additional potential royalty stream alongside the existing human-use arrangement.

The addendum announced on 31 July 2026 extends the licensing agreement with Splash Beverage Group and introduces a 10% perpetual royalty on veterinary net sales, while maintaining Argent's ownership of CannEpil intellectual property and development rights.

The expansion provides Argent with another potential commercial pathway for its cannabinoid-based medicine without requiring the company to directly fund additional development programs.

What Was Announced?

CannEpil® is Argent's cannabidiol-based medicine originally developed for epilepsy and neurological conditions.

In July 2026, Argent BioPharma (ASX:RGT), formerly known as MGC Pharmaceuticals, entered a licensing agreement with Splash Beverage Group covering human therapeutic applications of CannEpil.

That agreement included a 15% perpetual royalty on worldwide net sales and was structured partly as a debt-relief arrangement that helped Argent remove existing debt obligations.

On 31 July 2026, the companies signed Addendum No. 1, extending the licence to veterinary applications of CannEpil.

The expanded agreement provides Argent with a separate 10% perpetual royalty on veterinary net sales.

Argent retains all CannEpil intellectual property, manufacturing knowledge, regulatory Assets and development rights. The company has licensed commercialisation rights rather than transferring ownership of the underlying asset.

The veterinary program will progress through the U.S. Food and Drug Administration's Center for Veterinary Medicine pathways, including Investigational New Animal Drug (INAD) and Conditional Approval pathways.

Why This Matters

For Argent (ASX:RGT), expanding CannEpil into veterinary applications creates an additional potential Revenue pathway from an existing asset.

The licensing structure allows Splash Beverage and its collaborators to manage development, regulatory and commercial activities, while Argent retains potential royalty participation.

Royalty-based arrangements can provide smaller biotechnology companies with potential future revenue without requiring direct funding of large commercial infrastructure or clinical programs.

However, the value of the arrangement depends on Splash Beverage's ability to successfully fund, develop and commercialise CannEpil across human and animal markets.

Neither veterinary nor human CannEpil applications have received full Marketing approval, meaning royalty revenue remains dependent on future regulatory and commercial milestones.

Company Background

Argent BioPharma (ASX:RGT) is an Australian drug discovery and development company focused on cannabinoid-derived medicines.

The company develops proprietary formulations and uses licensing arrangements to commercialise products through external partners while retaining long-term royalty economics.

CannEpil is Argent's key commercial asset and is being positioned across human neurological applications and veterinary healthcare.

The company's strategy focuses on creating commercial opportunities through partnerships rather than directly funding all global development and distribution activities.

Financial Position

The primary CannEpil licensing announcement did not disclose Argent's current cash balance, Operating Cash Flow or funding runway.

The original licensing arrangement with Splash Beverage, reported at up to US$5.5 million in combined value, was used partly to eliminate existing debt obligations.

Future revenue to Argent from the agreement will primarily come through royalties on Splash Beverage's net sales once commercialisation occurs.

The company is therefore dependent on successful regulatory approval and commercial execution before meaningful royalty income can be generated.

Splash Beverage has disclosed financial challenges in recent filings, including US$381,195 in cash against US$16.97 million in current liabilities as of 31 March 2026.

What Comes Next?

The next steps for CannEpil's veterinary program will be managed by Splash Beverage and its veterinary collaborator Lupvindol as they progress through FDA Center for Veterinary Medicine pathways.

No specific timelines for veterinary regulatory submissions, approvals or commercial launch have been disclosed.

For the human CannEpil program, development remains under Splash Beverage's management, with no updated regulatory milestones disclosed in the available information.

Investors will monitor regulatory progress, partner funding capacity and future commercialisation updates.

Risks

Argent (ASX:RGT) faces counterparty execution risk because CannEpil commercialisation depends on Splash Beverage's financial capacity, regulatory progress and operational execution. Splash Beverage has disclosed financial uncertainty, which may affect development timelines. Both human and veterinary CannEpil programs remain subject to regulatory approval requirements. Argent's royalty-based structure limits direct control over commercial outcomes, while veterinary markets can involve different species, indications and adoption requirements.

Investor Takeaway

The expanded CannEpil licensing agreement provides Argent (ASX:RGT) with a second potential royalty pathway without requiring direct Investment into veterinary development activities.

The arrangement allows Argent to retain ownership of its intellectual property while external partners manage commercialisation activities.

However, the future value of the agreement depends heavily on Splash Beverage's ability to fund and execute development programs. Key areas to monitor include regulatory progress through veterinary pathways, partner financial capacity and advancement of the human CannEpil program.